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ABSTRACT
The rare pediatric embryonal tumors retinoblastoma, medulloblastoma and 
neuroblastoma derive from neuroectodermal tissue and share similar histopathological 
features despite different anatomical locations and diverse clinical outcomes. As 
metabolism can reflect genetic and histological features, we investigated whether the 
metabolism of embryonal tumors reflects their similar histology, shared developmental 
and neural origins, or tumor location. We undertook metabolic profiling on 50 
retinoblastoma, 39 medulloblastoma and 70 neuroblastoma using high resolution 
magic angle spinning magnetic resonance spectroscopy (1H-MRS). Mean metabolite 
concentrations identified several metabolites that were significantly different between 
the tumor groups including taurine, hypotaurine, glutamate, glutamine, GABA, 
phosphocholine, N-acetylaspartate, creatine, glycine and myoinositol, p < 0.0017. 
Unsupervised multivariate analysis found that each tumor group clustered separately, 
with a unique metabolic profile, influenced by their underlying clinical diversity. 
Taurine was notably high in all tumors consistent with prior evidence from embryonal 
tumors. Retinoblastoma and medulloblastoma were more metabolically similar, sharing 
features associated with the central nervous system (CNS). Neuroblastoma had features 
consistent with neural tissue, but also contained significantly higher myoinositol and 
altered glutamate-glutamine ratio, suggestive of differences in the underlying metabolism 
of embryonal tumors located outside of the CNS. Despite the histological similarities 
and shared neural metabolic features, we show that individual neuroectodermal derived 
embryonal tumors can be distinguished by tissue metabolic profile. Pathway analysis 
suggests the alanine-aspartate-glutamate and taurine-hypotaurine metabolic pathways 
may be the most pertinent pathways to investigate for novel therapeutic strategies. This 
work strengthens our understanding of the biology and metabolic pathways underlying 
neuroectodermal derived embryonal tumors of childhood.
INTRODUCTION
Pediatric solid tumors represent a diverse range 
of childhood cancers with unique anatomical location, 
cellular origins, and clinical presentation [1]. Tumors 
with an embryonic origin reflect a particular group of 
solid tumors that are derived from immature blast cells 
that fail to differentiate into normal tissue [1, 2]. Although 
these tumors can originate in many parts of the body, the 
most common locations in childhood include the liver 
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(hepatoblastoma), kidney (nephroblastoma), sympathetic 
nervous system (neuroblastoma), brain (medulloblastoma), 
and eye (retinoblastoma). The current study investigates 
the metabolic profile of the three main childhood 
embryonal tumors that arise from the neuroectodermal 
tissue of the nervous system, namely retinoblastoma, 
medulloblastoma, and neuroblastoma. 
Retinoblastoma is a tumor of the eye that develops 
from the precursor cells that form the retina. It occurs 
in very young children and has a good outcome with 
timely clinical intervention [3]. Neuroblastoma arises 
from the precursor cells of the neural crest-derived 
sympathetic nervous system, most commonly in the 
adrenal gland (60% of all cases) but can also develop 
from the sympathetic ganglia of the abdominal, thoracic, 
and pelvic regions [4, 5]. Although usually detected in 
children under two, neuroblastoma can also develop in 
older children, and has a heterogeneous clinical outcome 
[5]. Medulloblastoma is the most common malignant brain 
tumor of childhood and develops from the progenitor cells 
that form the cerebellum of the brain. Survival rates range 
from less than 45% to over 95% depending on molecular 
genetic subgroup [6]. Despite being very distinct clinical 
entities (Table 1), the microscopic appearance of these 
three tumor groups is often indistinguishable and they 
characteristically show a resemblance to tissue of the 
immature developing nervous system [7]. 
The presence of characteristic histopathological 
features such as rosettes is often evident, including Homer-
Wright rosettes which represent neural differentiation 
and Flexner-Wintersteiner rosettes which are a feature 
of retinoblastoma [7, 8]. The ectoderm, or external germ 
layer of the embryo, forms the basis of the nervous 
system including the spine, retina, brain, and peripheral 
nervous system, along with skin [9]. Although all three 
tumors develop from primitive neuroectodermal precursor 
tissue [1], structures of the central nervous system (CNS) 
including the cerebellum and retina arise from the neural 
tube, whilst the peripheral nervous system develops 
from the adjacent neural crest [9]. The tissue metabolic 
profile is known to reflect the molecular genetic and 
histological features of individual tumors [10], however it 
is unknown to what extent neural origin, tumor location, 
and developmental processes influence the metabolism of 
embryonal childhood tumors.
Ex vivo metabolite profiling of tumor tissue with 
high resolution magic angle spinning magnetic resonance 
spectroscopy (1H-MRS) has identified diagnostic and 
prognostic metabolite markers in a range of tumors [11]. 
We have previously shown medulloblastoma can be 
discriminated from other childhood brain tumors using 
1H-MRS, as well as evaluating glutamate as a prognostic 
marker [12, 13]. Furthermore, we have identified three 
main metabolic subgroups within retinoblastoma that 
correlated with histopathology and clinical features 
[14]. Metabolic profiling can also discriminate between 
MYCN-amplified and non-amplified neuroblastoma cell 
lines [15] and previous work by others has shown that it 
may be a useful method to distinguish stage [16]. These 
prior studies suggest that embryonal-derived tumor groups 
may share characteristic metabolic features associated 
with neural and neuroectodermal origin.
Tumors and brain disorders that occur within the 
CNS often contain imbalances in metabolites related to 
brain function. Prior research has linked the expression of 
N-acetyl Aspartate (NAA) and aspartate to both normal 
brain tissue and brain tumors [17]. NAA is known to be 
a marker of neuron number and integrity in normal brain, 
and is not found at high concentrations outside of the 
nervous system. Myoinositol is also characteristically 
seen in brain tumor tissue, particularly in tumors of 
glial origin [12, 18]. Interestingly myoinositol, creatine 
and NAA have been reported as the most important 
metabolites for discriminating brain region, further 
emphasizing their importance as neural metabolic markers 
[19]. Also of interest is the relationship between GABA, 
glutamate, and glutamine, which are classically regarded 
as neurotransmitters, but are known to independently 
influence tumor metabolism via the glutamate-glutamine 
cycle in cancer. Prior evidence indicates that taurine 
is notably elevated in primitive embryonal tumors, 
particularly those that are more differentiated [12, 14]. 
Although it is important in the developing brain, the 
function of taurine is largely unknown, aside from a role 
in neuroprotection. 
The influence of tumor location on metabolic 
profile may also be important. Medulloblastoma forms 
within the cerebellum, which is rich in metabolites related 
to neural function, and is likely to reflect this neural 
origin. Normal retina is one of the most metabolically 
active tissues in the body, with high levels of metabolites 
related to increased energy demands. Neuroblastoma 
most commonly arises within the adrenal medulla, which 
has high levels of glutamate, myoinositol, scylloinositol, 
catecholamines and acetate [20]. Although a proportion of 
neuroblastomas arise in the sympathetic ganglia at other 
locations, evidence suggests that sympathetic ganglia and 
adrenal medulla develop along a shared sympathoadrenal 
pathway and retain similar markers [21]. 
Deregulation of choline metabolism is considered 
to be a hallmark of most cancers and treatments targeting 
these pathways have shown promise in slowing cell 
proliferation and reducing tumor growth [22]. Choline 
metabolites and in particular phosphocholine (PC), are 
considered markers of malignancy, with elevated levels 
reported in more aggressive tumors and in comparison 
to normal tissue [11, 23, 24]. The relationship between 
choline metabolites is also of interest, with differences in 
the ratio of glycerophosphocholine (GPC) to PC reflecting 
different underlying molecular alterations in breast tumors 
[25], and high GPC indicative of a less aggressive tumor 
in brain [11, 12, 22]. Glycine is associated with high grade 
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in brain tumors [26], and is also elevated in many other 
tumors [24, 27]. Recent evidence has shown that rapidly 
proliferating cells display an increased reliance on glycine 
consumption and synthesis [28]. Although creatine is 
an important component of normal brain, prior studies 
have also associated increased creatine with increased 
energy metabolism in high grade brain tumors [11, 29]. 
Interestingly, creatine has been found to be particularly 
high in tumors of neuroectodermal origin [29].
Although many studies have investigated the tissue 
metabolic profile of medulloblastoma, retinoblastoma, and 
neuroblastoma individually, no study has yet compared the 
metabolomics of these three childhood embryonal tumors 
together. Previous studies have largely concentrated 
on identifying clinically relevant tumor subgroups 
and prognostic markers to benefit clinical decision-
making. The purpose of this study was to investigate 
the comparative metabolic profiles of these tumors and 
elucidate if the metabolic profile reflects the neural 
features typical of neuroectodermal origin, the location 
that the tumor arises from, or developmental metabolic 
processes. We quantified and analyzed 1H-MRS tumor 
spectra acquired from 159 retinoblastoma, neuroblastoma 
and medulloblastoma. This presents a unique and rare 
opportunity to directly compare metabolism in three rare 
pediatric tumors using the same methods and will further 
our understanding of the metabolism of neural-derived 
embryonal tumors and the factors that influence metabolic 
profile in childhood tumors.
RESULTS
Good quality spectra suitable for quantification 
purposes were available for 50 retinoblastoma, 39 
medulloblastoma and 70 neuroblastoma. All samples 
had a metabolite profile consistent with that expected 
of tumor. Twenty-eight metabolites were routinely 
detected and assigned within tumor spectra (Figure 1). 
Analysis of mean metabolite concentrations identified 12 
metabolites present at high concentrations (normalized 
mean concentration > 0.01) that were significantly different 
including aspartate, choline, phosphocholine (PC), creatine, 
glutamate, glutamine, glycine, hypotaurine, taurine, lactate, 
myoinositol, and NAA (Figure 2A, Supplementary Table 1). 
A further five low concentration metabolites (normalized 
mean concentration < 0.01) were also significantly different, 
including 3-hydroxybuturate (3HB), GABA, succinate, 
valine and scylloinositol (Figure 2B, Supplementary Table 
1). Lactate was the highest concentration metabolite present 
in all tumor groups. Although it is often excluded when 
comparing small tumor groups as it is sensitive to post-
biopsy metabolic degradation [10], our study suggests that 
despite increased variability in its concentration, there still 
appears to be a large difference in lactate concentration 
when considering these tumor groups as a whole. Lipids 
were observed in all three tumor groups, although mean 
concentration was particularly elevated in neuroblastoma 
(Figure 2C), interestingly high lipids in individual cases 
were generally associated with adverse clinical outcome. 
Table 1: Population demographics of each tumor type and the characteristics of the samples 
included in this study
Retinoblastoma Medulloblastoma Neuroblastoma
Population and clinical characteristics
Anatomical location eye brain (cerebellum) sympathetic nervous system (various locations)
Mean age at diagnosis 18 months 5–6 years 2–3 years
% of all childhood cancers 
(0–14y) ; USAaUK b
3% (280 per year)
3% (44 new cases per year)
3.8% (400 per year)
3.5% (54 new cases per 
year)
7% (710 per year) 6% (78 
new cases per year)
Gender distribution (F:M); 
Range: USAa-UK b 48–50% 60–65% 53–55%
5Y overall survival rate; 
Range: USAa-UK b
99% 65–71.3% 65%–79%
Characteristics of tumor samples included in this study
Sample numbers n = 50 n = 39 n = 70
Period samples collected over 2004–2013 1999–2013 1996–2012
Mean age at diagnosis (years) 1.5 6.5 2.5
Gender distribution 37% male 75% male 60% male
5Y survival rate 100% 60% 67%
aReported in Mathew et al., Neuro-oncology 2014 [59] bStatistics reported on CRUK website cReported in Ward et al., CA 
Cancer J Clin 2014 [60].
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All three tumors display metabolic features 
characteristic of neural tissue
NAA and aspartate were detected in all three 
tumor groups, consistent with these metabolites being 
markers of neural-derived tissue [30]. The concentration 
of both NAA and aspartate in this study was highest 
in neuroblastoma, followed by medulloblastoma and 
retinoblastoma. NAA has been detected at low levels in 
neuroblastoma and normal adrenal medulla previously 
[16]. As expected, very low levels of NAA were seen 
in medulloblastoma compared to that evident in normal 
brain [23]. A markedly elevated mean concentration of 
myoinositol was evident in neuroblastoma, with moderate 
amounts in medulloblastoma and very little detected in 
retinoblastoma, p < 0.0001, Figure 2A, Supplementary 
Table 1. Although typically described as a glial marker 
it is unclear what the significance of myoinositol is in 
neuroblastoma. Creatine is often reported as a marker 
of neural tissue, and has been used to discriminate brain 
tumors with high energy demands. It was present in all 
three tumor groups, consistent with prior evidence of 
increased levels in neuroectodermal tumors [29, 31] 
but was significantly higher in medulloblastoma (p 
< 0.0017). Other neural markers such as GABA and 
glutamate were evident at varying concentrations in the 
three tumors. These metabolites play an important role in 
cancer metabolism in many tumor types throughout the 
body independent of their role in neural tissue [31, 32]. 
Therefore their concentration may be influenced by tumor 
location and the malignant properties of the tumor groups 
rather than solely as neural metabolites. 
Taurine is associated with both neural and 
developmental origins in embryonal tumors
Although taurine has been routinely identified in 
many types of brain tumors previously, the concentration 
of taurine was particularly prominent in all three tumor 
groups in this study. Elevated taurine has been previously 
detected in tumors of neuroectoderm embryonal origin 
relative to both its concentration in normal brain and in 
other non-embryonal brain tumors [12, 29]. A significant 
difference in concentration between each tumor 
was evident, with retinoblastoma having the highest 
concentration, followed by medulloblastoma, then 
neuroblastoma, p < 0.0001, Figure 2A, Supplementary 
Table 1. The concentration of hypotaurine, followed the 
pattern evident with taurine concentration, however it 
was absent in neuroblastoma, resulting in a hypotaurine 
to taurine ratio of 0, which was significantly decreased 
compared to retinoblastoma (0.173 ± 0.03, mean ± SEM) 
and medulloblastoma (0.210 ± 0.03), p < 0.0001. 
Tumor location influences metabolic profile
Both the location of the tumor itself and the function 
of the normal tissue that each tumor derives from, appears 
to influence metabolic profile. Although taurine is elevated 
in embryonal tumors, the concentration of taurine present 
Figure 1: Example spectra from each tumor group, retinoblastoma, medulloblastoma, and neuroblastoma. Assigned 
metabolites are labelled on relevant spectra; 3-hydroxybuturate (1), acetate (2), acetone (3), alanine (4), ascorbate (5), aspartate (6), beta-
d-glucose (7), choline (8), creatine (9), GABA (10), glutamate (11), glutamine (12), glutathione (13), glycerophosphocholine (14), glycine 
(15), hypotaurine (16), isoleucine (17), lactate (18), leucine (19), myoinositol (20), NAA (21), phosphocholine (22), phosphoethanolamine 
(23), scylloinositol (24), serine (25), succinate (26), taurine (27), valine (28), lipid (Lip 1: 0.9ppm component and Lip 2: 1.3ppm component). 
(A) Detailed view of the choline region. (B) Detailed view of the glutamate/glutamine region. Note; each metabolite has been labelled on 
only one of the example spectra, to improve the clarity of the figure.
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in retinoblastoma and medulloblastoma also appears 
to be influenced by the high concentration of taurine in 
normal retina and cerebellum [19, 33, 34]. Succinate was 
also significantly elevated in retinoblastoma compared to 
medulloblastoma and neuroblastoma, p < 0.0001. This 
is notable given that succinate has been proposed as a 
metabolic driver of angiogenesis and neovascularization 
in retina and retinal disease [35]. It was also evident that 
lactate is notably higher in retinoblastoma than the other 
tumors, p < 0.0001. Lactate is the highest concentration 
metabolite in the retina and is known to be a viable 
energy source for metabolism in retinal tissue [36]. 
The significantly higher expression of GABA within 
retinoblastomas, p < 0.0001, (Figure 2B, Supplementary 
Table 1), is likely influenced by the high concentration 
of GABA detected in normal retina. Furthermore, GABA 
was noted at similar concentrations in a small number of 
medulloblastomas (n = 4), which may reflect molecular 
genetic subgroup [37]. GABA has not been reported in 
normal adrenal medulla [20], and was not detected in 
neuroblastoma in this study. Although scylloinositol, 
has been reported as a marker of poor prognosis in 
individual cases, the 3 fold increase in mean concentration 
in neuroblastoma and medulloblastoma compared to 
retinoblastoma (p < 0.0001), may be influenced by 
the metabolic profile of normal adrenal medulla and 
cerebellum. Scylloinositol has been detected in these 
locations previously [16, 20, 33] however it does not 
appear to be present in normal ocular tissue [34]. The 
catecholamine’s typically seen in adrenal medulla were 
undetectable in neuroblastoma, consistent with a prior 
study [16, 20]. 
Differences in metabolites are characteristic 
of individual tumors and their proliferative 
capabilities
A number of metabolites were identified that are 
characteristic of tumors in general including elevated PC, 
glycine, and scylloinositol. Unsurprisingly PC was the 
second most highly concentrated metabolite in all three 
tumor groups after lactate, with the highest concentration 
in medulloblastoma followed by neuroblastoma, then 
retinoblastoma (p < 0.001, Figure 2A, Supplementary 
Table 1). GPC was unchanged between the three groups, 
however free choline was significantly elevated in 
both medulloblastoma and neuroblastoma compared 
to retinoblastoma, p < 0.0001. Differences in choline 
metabolism are also indicated by changes in the ratio of 
GPC to PC with a significantly lower ratio evident in 
medulloblastoma, 0.16, p < 0.0001, Figure 3A. 
In addition to PC, medulloblastoma also had 
significantly increased mean concentration of glycine 
(p < 0.001) compared to the other two tumor groups. 
This suggests that both glycine and PC distinguish 
increased cellular proliferation and energy metabolism 
in medulloblastoma. Glutamate and glutamine are of 
particular interest in cancer metabolism. Interestingly 
neuroblastoma displayed the most significantly different 
glutamate-glutamine metabolism, with glutamate 
increased by 2-fold (p < 0.001) compared to the other 
tumors and glutamine reduced by half (p < 0.001). A 
markedly higher mean ratio of 4.71:1, of glutamate 
to glutamine was also evident, p < 0.0001, Figure 3B, 
(range: 2.23-11.21). In comparison the mean ratios for 
Figure 2: Differences in mean metabolite concentrations between retinoblastoma (n = 50), medulloblastoma (n = 39), 
and neuroblastoma (n = 70). (A) High concentration metabolites. (B) Low concentration metabolites. Data expressed as normalized 
mean concentration ± standard error, SEM. * indicates statistical significance detected between tumor groups with Kruskall-Wallis, p < 
0.0017 (Bonferroni corrected). (C) Mean total lipid concentration, p = 0.001 Kruskall-Wallis, +statistical significance between groups with 
Mann-Whitney U post hoc test, p < 0.05. PE; phosphoethanomine, MI; myoinositol, SI; scylloinositol.
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retinoblastoma and medulloblastoma were 1.07 and 1.18 
respectively (Figure 3B). 
The presence of lipid was variable in each tumor 
type, with neuroblastoma having a higher proportion of 
tumors with markedly elevated lipids, and a 2-fold higher 
mean lipid concentration than both retinoblastoma and 
medulloblastoma, p < 0.002 (Figure 2C). Interestingly, 
lipid was markedly elevated in all MYC and MYCN 
amplified neuroblastoma and medulloblastoma. The 
remaining medulloblastomas generally had very low 
concentrations. The mean concentration of lipid in 
MYC/MYCN tumors (5.65 ± 1.26, mean ± SEM) was 
significantly higher than in negative tumors (1.40 ± 0.22, 
p = 0.001). 
Metabolite differences can distinguish the 
different embryonal tumor groups
Next, we investigated the influence of tumor 
location, developmental and neural features, and individual 
tumor properties on tumor clustering in a multivariate 
analysis. Metabolite concentrations from each tumor 
were entered into a principal components analysis (PCA). 
Serine, acetone, phosphoethanomine and glutathione were 
excluded, as they were present at very low concentrations, 
and were not significantly different between tumor groups. 
The PCA showed little overlap between the three tumor 
groups (Figure 4A). Retinoblastoma and neuroblastoma 
were the most separated in principal component 1. 
Medulloblastoma appears to be more distinct in principal 
component 2, although this component is responsible 
for much less of the inter-tumor variation. Particular 
metabolites strongly influence the clustering of each tumor 
group within the PCA (Figure 4B). In retinoblastoma, 
lactate, succinate, GABA, and the branch chain amino 
acids valine, leucine and isoleucine are particularly 
elevated, whilst for medulloblastoma, glycine and PC are 
increased. Together, medulloblastoma and retinoblastoma 
have much higher taurine, hypotaurine, glutamine, 
creatine and ascorbate than neuroblastoma. Markedly 
elevated glutamate and myoinositol in comparison to 
the other groups were the most influential metabolites in 
neuroblastoma. Hierarchal dendrogram analysis identified 
almost complete separation between the three groups, with 
medulloblastoma and retinoblastoma clustering closely 
together and neuroblastoma appearing to be a more 
distinctly separate group. 
Relationships between metabolites have 
identified several key metabolic pathways that 
are altered
We also determined if differences were evident in 
metabolite correlations and metabolic pathways across the 
entire tumor cohort (Figure 5). As expected several pathway-
related metabolites were positively correlated with each 
other including PC, GPC, and free choline, myoinositol and 
scylloinositol, taurine and hypotaurine, and the branched 
chain amino acids. Significant positive correlations were 
identified between metabolites previously associated with 
poor prognosis, including the choline metabolites, glutamate 
and scylloinositol. Glutamate and glutamine were negatively 
correlated with each other overall. When metabolite 
correlations were investigated within each individual tumor 
group, PC, glycine, and glutamate were strongly positively 
correlated in retinoblastoma and negatively correlated with 
taurine (Figure 5). In medulloblastoma, glutamate was 
positivity correlated with glycine, but negatively correlated 
Figure 3: Metabolite concentration ratios differ between tumor groups. (A) The ratio of GPC to PC and (B) the ratio of 
glutamate to glutamine is significantly different between tumor groups, p = 0.0001, Kruskall-Wallis, *indicates statistical significance 
detected between groups with Mann-Whitney U post hoc test, p < 0.05. Data expressed as mean ratio ± SEM. 
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with PC. Glutamine was strongly positively correlated 
with glutamate in retinoblastoma, negatively correlated in 
medulloblastoma, and not correlated in neuroblastoma. A 
similar pattern was evident with taurine and hypotaurine in 
retinoblastoma and medulloblastoma.
Pathway analysis showed the alanine, aspartate, and 
glutamate metabolic pathway was the most significantly 
altered between all three tumor groups with a pathway 
impact value of 0.75 out of 1, p = 0.00001 (Figure 6). The 
taurine and hypotaurine pathway was also significantly 
altered, with an impact value of 0.41, p = 0.0002. Other 
significantly different pathways included inositol phosphate 
metabolism (impact value 0.14, p = 0.00249), glycine, 
serine and threonine metabolism (0.19, p = 0.0001) and 
glycerophospholipid metabolism (0.19, p < 0.00239). 
Within each individual tumor group, the alanine, aspartate, 
glutamate metabolic pathway remained the most altered 
pathway, however the impact value was decreased in 
neuroblastoma (0.41) compared to retinoblastoma (0.70) and 
medulloblastoma (0.75).
DISCUSSION
To our knowledge this is the first study to carry 
out a parallel investigation of these three neural derived 
embryonic tumors, retinoblastoma, medulloblastoma and 
neuroblastoma, using metabolomics. This study addresses 
the underlying influence of tumor location, origin and 
development on the metabolism of these three embryonal 
tumors. Metabolites related to neural origin were 
evident in all three tumors, with the greatest similarities 
noted between retinoblastoma and medulloblastoma. 
Nevertheless all three tumors clustered separately based 
on the complete metabolic profile (Table 2), emphasizing 
the unique features of each tumor type, related to their 
development and location. 
Tumors derived from neuroectodermal tissue 
retain some neural features
Small amounts of NAA were evident in 
medulloblastoma, indicating that these tumors do retain 
neural metabolic features, perhaps unsurprising given 
that brain tumors often contain NAA. It is possible that 
the NAA reflects trapped neuronal elements within 
the tumor, although the concentration present within 
tumors was not consistent with the presence of large 
amounts of normal brain. Very little NAA was detected in 
retinoblastoma, possibly influenced by it being of much 
lower concentration in retina compared to other areas of 
the CNS [30]. Notably NAA, aspartate and acetate were all 
highest in neuroblastoma, suggesting that neuroblastoma 
Figure 4: Embryonal tumor groups cluster separately in unsupervised multivariate analysis using metabolite 
concentrations. (A) PCA scores plot demonstrating separate clusters for neuroblastoma (n = 70, squares), medulloblastoma (n = 39, 
triangles) and retinoblastoma (n = 50, circles) from left to right in principal component 1. (B) PCA scores biplot showing the metabolites 
elevated in each cluster. (C) Dendrogram analysis with Euclidian distance measure and Wards clustering method demonstrates that 
neuroblastoma tumors cluster to the left on their own branch. Medulloblastoma and retinoblastoma originate from the same right side 
branch, then divide and cluster separately. MI = myoinositol, SI = scylloinositol, PC = phosphocholine.
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shares features consistent with nervous tissue. However 
it is becoming evident that NAA may have a much 
wider role in tumors, with high levels associated with 
poor outcome in several tumors that occur outside of the 
nervous system [38]. Although NAA did not appear to be 
present in normal adrenal medulla, it has been detected in 
pheochromocytoma, a tumor that also derives from adrenal 
medulla. Creatine was elevated in medulloblastoma, 
perhaps reflecting not only increased energy metabolism 
in this tumor, but also that the cerebellum has been 
Figure 5: Differences in inter-metabolite correlations were evident between tumor groups. Groups of highly correlated 
metabolites in the heat map containing all tumors (n = 159) are clustered together using hierarchal clustering. The individual tumor heat-
maps were then ordered in a supervised manner according to the same pattern seen in the all tumors comparison, to identify if the similar 
patterns occurred in each tumor group. Dark red indicates a strong positive correlation between two metabolites (Pearson’s correlation 
r = 1 for a perfect positive correlation), dark blue indicates a strong negative correlation (Pearson’s correlation r = -1 for a perfect negative 
correlation). Only significant correlations are shown, non-significant correlations are left blank. 
Table 2: Summary of key metabolite differences between neural-derived embryonal tumors
Retinoblastoma Medulloblastoma Neuroblastoma
Taurine High Intermediate Low
Hypotaurine High Intermediate Absent
Glutamate Intermediate Intermediate High
Glutamine Intermediate Intermediate Low
GABA High Low Absent
Phosphocholine Low High Intermediate
Myoinositol Very low Intermediate High
Glycine Low High Intermediate
NAA Low Intermediate High
Creatine High High Low
Oncotarget11344www.impactjournals.com/oncotarget
purported to contain the highest concentration of creatine 
when compared to other brain regions including frontal 
cortex, brainstem, and hippocampus [19]. 
Myoinositol is regarded as an osmolyte, with a 
possible role in cell signaling, although very little is 
known about its function. It is notably raised in the 
CNS, suggesting it has a particular role within neural 
tissue [18]. In pediatric brain tumors, notably elevated 
myoinositol is evident in ependymoma compared to 
pilocytic astrocytomas and medulloblastoma [39]. 
Elevated myoinositol has not been previously reported in 
neuroblastoma tissue, although an association with patients 
diagnosed at younger ages (< 2Y) was noted by Imperiale 
[16]. We found a moderate concentration of myoinositol in 
medulloblastoma consistent with previous studies [12, 39]. 
The almost complete absence in retinoblastoma suggests 
that it is not a feature of this tumor. 
Metabolic profile of each respective normal 
tissue influences tumor metabolic profile
The metabolic profile of medulloblastoma is 
influenced by its neural origins, and its location within the 
cerebellum of the brain. Cerebellum is known to contain 
high taurine, and creatine, and low myoinositol relative to 
other areas of the brain [19, 29, 33], consistent with the 
profile of medulloblastoma in the current study. Previous 
work investigating metabolism in normal retina obtained 
from post-mortem tissue has shown that it is particularly 
high in lactate, taurine, GABA, creatine, succinate, and the 
branched chain amino acids valine, leucine and isoleucine 
[34], likely reflecting its increased metabolic rate relative 
to other tissues within the body [40]. The metabolic profile 
of retinoblastoma was consistent with this. Although 
myoinositol has been detected at high concentration in 
normal adult retina [34], it was at very low concentration 
in retinoblastoma. It may be that myoinositol is present 
at higher concentrations in adulthood. Normal adrenal 
medulla has high levels of taurine, glutamate, myoinositol, 
scylloinositol, and the catecholamines adrenaline and 
noradrenaline, relative to adrenal cortex [20] which 
develops from the mesoderm rather than the neural 
crest [41]. The metabolic profile of neuroblastoma 
seems to closely reflect the profile of adrenal medulla. 
Furthermore, glutamate and myoinositol also appear to 
be present at high concentrations in pheochromocytoma 
and paragangliomas, tumors which also derive from the 
adrenal medulla [42]. 
Metabolism in embryonal derived tumors is 
influenced by developmental processes
Taurine was elevated in all three tumor groups 
compared to non-embryonal tissue consistent with prior 
Figure 6: The alanine/glutamate/aspartate metabolic pathway was the most significantly different pathway between 
all three tumor groups. Five metabolites were highly significant across this pathway, p < 0.0001(indicated by solid boxes with blue 
shading). Glutamine was also significant, p < 0.001, dotted box. Alanine was not significantly different. Metabolites in small text with no 
borders were not detected by 1H-MRS methods. This pathway is a modified metabolic pathway from KEGG database.
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reports of it being present at higher concentrations in 
neuroectodermal derived tissue [12, 29]. A known cellular 
osmolyte, it is also a neurotransmitter, with taurine-
specific synthesizing enzymes, receptors and transporters 
present within the CNS [43]. However it appears that 
taurine concentration is also influenced by developmental 
processes. It is known to be essential in neonates for 
normal brain development and depletion can result in 
long term deficits in brain function. A clear age gradient 
of brain taurine content is evident from mouse and human 
studies with concentration being much lower in adult brain 
than in early postnatal life [33, 44]. Higher concentrations 
of taurine may relate to the specific role of taurine within 
the early development of the retina and cerebellum. In 
retina it is particularly important for rod photoreceptor 
development from retinal precursor cells, whilst in the 
cerebellum it is important for correct migration of the 
precursor cerebellar granular neuronal cells [43]. It is also 
known to influence differentiation of neural precursor 
cells in these regions during development [45]. In many 
adult cancers, elevated taurine is associated with high 
grade and poor survival including pancreatic, colorectal, 
and prostate cancer [10]. However in retinoblastoma, it 
is more closely associated with the better differentiated 
clinicopathological sub-group, further emphasizing its role 
in differentiation during development [14]. Taurine was 
lower in neuroblastoma suggesting that it may not be as 
influenced by developmental processes occurring outside 
of the brain. Taurine content in individual neuroblastomas 
may indicate poor survival outcome, as shown by a 
previous study [16]. Although little is known about the 
role of hypotaurine, we have shown that the taurine/
hypotaurine pathway is of importance and warrants further 
investigation, particularly in neuroblastoma.
Differences in particular metabolites are 
associated with underlying clinicopathological 
risk factors 
PC, a component of the total choline signal in 
tumors was also significantly different between all 
three tumor types. Changes in choline metabolism are 
typically associated with many types of malignancy. 
Medulloblastoma had the highest concentration of 
the three tumors, consistent with prior studies [12]. 
Although PC has not previously been associated with 
outcome in neuroblastoma patients, the lower mean 
concentration may reflect the wide range of stage and 
outcomes in the neuroblastoma cohort included in this 
study. Retinoblastoma had the lowest concentration 
of PC. Despite this, it is still known that PC correlates 
with adverse histology and greater clinical risk in 
retinoblastoma [14]. The ratio of GPC to PC may be an 
additional indicator of malignant status in brain tumors, 
with a higher ratio of GPC to PC linked to less aggressive 
behavior [25]. Tumor proliferation measured by Ki67 
index is typically high in most medulloblastomas, but 
more variable across retinoblastoma and neuroblastoma. 
Whilst it is evident that altered choline metabolism likely 
reflects malignant behavior in each of the tumor groups, it 
seems apparent that high PC may also reflect the cellularity 
of the tumor, rather than solely an increase in relative 
aggressiveness between groups. Interestingly glycine, 
another marker of adverse outcome [26, 27], was also 
elevated in medulloblastoma. However unlike PC which 
was elevated in almost all medulloblastomas, glycine was 
notably raised in those cases with poor survival. 
The role of glutamate and glutamine metabolism 
within these three tumor groups is also of interest, 
particularly in neuroblastoma where glutamine was at 
markedly low concentration, and glutamate was very 
high. A mean imbalance in glutamate is not evident in 
medulloblastomas as a whole, although it is apparent that 
high glutamate and altered ratios of glutamate to glutamine 
seems to be of prognostic significance [13]. Almost all 
neuroblastomas in this study had high glutamate, and 
in particular, an imbalance in the ratio of glutamate to 
glutamine, even those with low risk disease. There is 
strong evidence for altered glutamine metabolism being of 
diagnostic and prognostic significance in the neuroblastoma, 
and it is possible that there is change in flux within the 
glutamate-glutamine cycle [46]. This has been reported in 
other tumors and will require further investigation.
The identified association between high risk 
MYC and MYCN driven tumors and elevated lipids in 
medulloblastoma and neuroblastoma is also notable. 
Previous studies in lymphoma, lung and liver cancers 
have also reported changes in lipid composition, signaling 
and metabolism with MYC amplification [47–49], 
suggesting that the relationship between MYC and 
lipids is not restricted to tumors developed from neural 
derived tissue. Indeed in lymphoma, mass spectrometry 
imaging has identified a unique lipid signature that is 
characteristic of MYC driven disease, whilst non-MYC 
lymphoma has a different underlying lipid metabolic 
profile [47]. A similar finding has also been reported in 
lung tumors [48]. This may be important for specifically 
targeting inhibition of MYC driven tumors, which have 
a particularly poor patient outcome. Recently it has been 
found that therapeutic targeting of MYC using small 
molecule inhibitors can disrupt lipid metabolism through 
mitochondrial dysfunction [50, 51]. Although we have 
only assessed total lipid by 1H-MRS in tumor tissue, it is 
highly likely that both MYC/N amplified neuroblastoma 
and medulloblastoma have altered lipid signatures, and 
that therapeutic targeting of lipid metabolism may offer 
a potential avenue for directed treatment in these high 
risk cases. There is a known association between elevated 
lipids and poor outcome in non-MYC/N driven brain 
tumors [52], hence ongoing investigation of underlying 
lipid metabolism and the relationship to other metabolic 
pathways in cancer is essential. 
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Retinoblastoma and medulloblastoma are most 
metabolically similar, whilst neuroblastoma is 
more distinct
The two tumors that appear most metabolically 
similar are retinoblastoma and medulloblastoma. It 
is evident that both contain large concentrations of 
metabolites reflecting both CNS neural origin and 
similarities in metabolic function during development. 
Despite this, these two tumors can be distinguished, 
with retinoblastoma containing relatively higher levels 
of metabolites that seem to reflect the increased energy 
demands of normal retina. Moreover medulloblastoma is 
distinguished by elevated PC, glycine and scylloinositol, 
markers of increased cellularity, high proliferation and 
poor clinical prognosis in brain tumors. Neuroblastoma 
had a distinct metabolic profile that was markedly 
different from the other two groups, with less taurine, 
very little glutamine and elevated myoinositol and 
glutamate. Although these embryonal tumors all derive 
from primitive neuroectodermal tissue, neuroblastoma 
arises from the neural crest rather than the neural tube 
and occurs throughout the sympathetic nervous system. 
Therefore it may not represent as closely the metabolic 
features seen in retinoblastoma and medulloblastoma 
which originate in the CNS. The developmental influences 
on tumor metabolism are also likely to be different outside 
of the CNS. Moreover, recent debate suggests that neural 
crest derived tumors should be considered separate entities 
from neuroectodermal tumors of the CNS despite similar 
histological features and origins [53]. 
Although a direct comparison with the underlying 
histology of each tumor is outside the scope of this work, 
there is typically more heterogeneity in the underlying 
neuroblastoma pathology, including a higher stromal 
component [4] not typically seen in medulloblastoma or 
retinoblastoma. Although we have not previously found 
intra-tumor heterogeneity to influence metabolic profile 
in neuroblastoma tissue [12], there is more underlying 
variation in metabolic profile between samples in the 
neuroblastoma group which may reflect heterogeneity in 
underlying histology. This will be examined in future work 
in the neuroblastoma cohort.
MATERIALS AND METHODS
Clinical data
Frozen tumor tissue was collected over a period 
from 1996–2016 from biopsied or surgically resected 
medulloblastoma, neuroblastoma and retinoblastoma 
patients and stored at –80 degrees. Tissue was obtained 
from the Birmingham Children’s Hospital tumor bank 
and the UK Children’s Cancer and Leukaemia Group 
(CCLG) tumor bank (neuroblastoma and retinoblastoma 
only). Consent was obtained for tissue banking for 
ethically approved research from the local Research Ethics 
Committee and the CCLG Biological Studies Committee 
(neuroblastoma and retinoblastoma). All medulloblastoma 
and retinoblastoma patients were treated locally at 
Birmingham Children’s Hospital, some neuroblastoma 
tissue was obtained from other treatment centers via 
CCLG. Pathology reports, and limited clinical and survival 
data were available for all cases (Table 1). The cohort of 
tumors under investigation represented a wide range of 
molecular and clinical stages. Of the 50 retinoblastoma 
patients, four had bilateral disease and the remaining had 
unilateral disease, and all cases were sporadic rather than 
familial. This cohort has been described previously [14]. 
The 39 medulloblastoma cases were distributed across 
the histological variants namely, large cell anaplastic, 
desmoplastic nodular, and classic. One medulloblastoma 
was MYC amplified, whilst two were MYCN amplified. 
The 70 neuroblastoma samples included cases from low 
and high stage disease (1, 2, 3, 4 and 4S). Eleven of the 53 
stage 3 & 4 neuroblastoma were MYCN amplified. 
High-resolution proton magnetic resonance 
spectroscopy (1H-MRS)
Briefly, frozen tissue was weighed, trimmed to 
fit in either a 50ul or 12ul zirconium rotor and 5ul of 
internal standard was added (TSP Cambridge Biosciences, 
Cambridge, UK), before the rotor was topped up with 
deuterated water (Sigma-Aldrich, Dorset, UK). There 
were no samples where the volume of liquid was 
inaccurate or spilled during preparation hence no effect 
of this on subsequent metabolite quantification in any 
samples. 1H-MRS was undertaken on a Bruker Avance 
500MHz spectrometer using a 4mm 3 channel HR-
MRS z-PFG band probe (Bruker, Coventry, UK) at the 
Henry Wellcome Building for Biomolecular NMR at 
the University of Birmingham. All data was acquired 
over a period from 2011-2016. Tumor tissue was kept 
cold over dry ice during preparation and the temperature 
was maintained at 4◦C whilst acquiring data to minimize 
metabolite degradation. Samples were spun at 4800Hz 
with a pulse-acquire sequence with 2s of NOESY 
presaturation for water suppression and a repetition time 
of 4s. The total acquisition time was 17 or 34 minutes 
depending on sample size and signal to noise ratio. The 
mean sample weight and standard deviation for each 
tumor group was 20 ± 10.2 for medulloblastoma, 21 ± 7.8 
for retinoblastoma, and 22 ± 14 for neuroblastoma. 
Data pre-processing and quality control
All processing of raw 1H-MRS spectra was 
undertaken in Mestrenova v9.0.1 (Mestrelab Research, 
Santiago, Spain). Spectra were Fourier-transformed, 
manually phased, automatically baseline corrected and 
chemical shift referencing performed relative to creatine 
at 3.03ppm. All spectra were visually inspected prior to 
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undertaking quantification and only samples with high 
signal to noise and well defined metabolite peaks were 
used for further analysis. Whilst there is the potential for 
inaccuracies in quantification due to the hydrophobic 
interactions between internal standard TSP and 
membrane bound constituents in tissue, quality control 
procedures ensured that this was minimized. All TSP 
peaks were reviewed to assess the signal and confirmed 
to consist of a narrow well defined singlet with a 
consistent peak shape and linewidth at 0.0ppm. Due to 
the rarity of the tumor tissue under investigation and the 
need to maximize its availability for other molecular 
analyses, it was not possible to check the histology 
of every tissue sample in this cohort after 1H-MRS. 
However, previous analysis of post-MRS samples in a 
limited number of retinoblastoma [14], and other neural 
tissue (unpublished) provides a clear indication of the 
presence of tumor tissue versus normal tissue. Highly 
elevated phosphocholine, glycine, and lactate along with 
the presence of lipids and low NAA was used as a marker 
of spectra containing predominantly tumor. Samples 
with a large amount of normal neural tissue typically 
contain a much higher ratio of creatine to choline, a 
high ratio of GPC to PC and choline, very high NAA 
and lower glycine than tumor tissue. These definitions 
are consistent with prior studies reported in the literature 
[19, 20, 26, 54]. All of the tumor spectra included this 
study were assessed using these criteria and had features 
consistent with tumor. 
Quantification of metabolite concentrations
The region from 0-4.7ppm was analyzed for 
metabolite concentrations. Metabolites were manually 
assigned according to published literature and the 
Human Metabolome Database (HMDB) [55, 56]. 
Automatic peak detection using the global spectral 
deconvolution algorithm within Mestrenova was 
applied to the spectra to detect peaks. Metabolite 
assignments used for quantification are provided in 
Supplementary Table 1. Quantification of metabolite 
concentrations was undertaken relative to the 
internal standard, TSP. Using the qNMR function 
within Mestrenova, the fitted area of the assigned 
metabolite peak was compared to the fitted area of 
the TSP at known concentration, and adjusted for the 
proton number of the metabolite and TSP to obtain 
concentration values. Broad resonances originating 
from the main lipids peaks from 0-6ppm were assigned 
as described previously [14], Supplementary Table 
2, and quantified as described above. Lipid data is 
presented as the total sum of lipid. Metabolite and total 
lipid concentrations were normalized to the total sum 
of all metabolites within the sample. Metabolite ratios 
between selected metabolites were obtained using the 
raw pre-normalized concentration values. 
Statistical analysis
Mean metabolite concentrations and ratios were 
statistically analyzed in SPSS (NY, USA) using non 
parametric Kruskall-Wallis tests with a Bonferroni adjusted 
significance value of p = 0.0017, to correct for multiple 
comparisons across metabolites. Where significance was 
achieved, pair wise post-hoc comparisons were undertaken 
with the Mann-Whitney U test. Multivariate analysis was 
undertaken using Metabaloanalyst (Version 3.0) and R 
[57]. Unsupervised PCA and dendrogram cluster analysis 
were carried out with metabolite concentrations as input. 
Euclidian distance measure and Wards clustering method 
were used for dendrogram analysis. Inter-metabolite 
correlations and heat maps were calculated with Pearson’s 
correlation measure. 
Pathway analysis was also undertaken in 
Metabaloanalyst, using the pathway topography analysis 
module. This analysis uses the structure of the pathway 
to evaluate the importance of the metabolites within the 
pathway, and identifies the most relevant altered pathways 
between different groups [57, 58]. For this analysis, the 
homosapiens pathway library was used, with the global 
test method to evaluate differences between each tumor. 
Relative betweeness centrality was used to evaluate the 
importance of each metabolite within the pathways. 
Pathway impact values, scored out of 1, are presented with 
significant p values calculated using the false discovery 
rate (FDR) which is adjusted for multiple comparisons. 
CONCLUSIONS
Despite the histological similarities and neural 
metabolic features shared by all three tumors, this work 
shows that neuroectodermal derived embryonal tumor 
groups can be distinguished by tissue metabolic profile. 
It is apparent that some aspects of metabolism reflect 
the known characteristics of each individual tumor type, 
whilst others reflect developmental processes and the 
metabolic function of the normal tissue that these tumors 
derive from. Several metabolites and biological pathways 
including taurine, glutamate/glutamine, and myoinositol 
have been identified that are of prognostic and diagnostic 
interest and require further investigation in these tumors. 
We have also identified a relationship between elevated 
MYC/N and lipids. Although we have not endeavored to 
directly link clinical or pathological features to metabolites 
across the cohort in this study, ongoing parallel work in 
individual tumor groups shows promise for untangling the 
relationship between molecular features and metabolism 
[37], as well as the potential to identify non-invasive 
biomarkers using in vivo magnetic resonance spectroscopy. 
This is the first study to undertake comparative metabolic 
analysis of this rare group of pediatric tumors and it 
provides valuable insight into our understanding of tumor 
metabolites in childhood cancers. This work furthers our 
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understanding of the biological pathways of childhood 
tumors derived from the neuroectoderm and may aid in 
identification of pathways to target for the development 
of novel therapeutics in this group of tumors.
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